Novel approaches and agents are needed to improve the outcome of patients with high-risk myelodysplasia (MDS) and acute myeloid leukemia (AML). In MDS or secondary AML, intensive chemotherapy (ICT) results in low complete remission (CR) rates (40-60%) and short CR duration (median duration, 10-12 months). Complex karyotype is the most important adverse prognostic factor of response to ICT. 1 Moreover, the feasibility of ICT is also impaired by the advanced median age of patients with MDS and the comorbidities of patients with secondary AML.
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for high-risk MDS and AML. Unfortunately, only a minority of patients is eligible for HSCT, because of comorbidities and advanced age of recipients and their potential donors, as well as difficulties to assess disease control underlining the need of novel strategies, particularly in case of complex cytogenetics.
The use of hypomethylating agents has dramatically transformed the prognosis of MDS patients who cannot benefit from an ICT program. Those molecules have, for the first time, significantly improved the overall survival (OS) of MDS with blast's excess, with a prolonged median OS of 9 months in patients treated with azacitidine, as compared with those receiving conventional care regimens. 2 Azacitidine appears also interesting in AML, with 32% overall response in an Italian compassionate program, 3 and the report of prolonged OS in older patients with low marrow blast counts AML. 4 Despite these encouraging results, the prognosis of high-risk MDS and AML remains poor. 5 Lenalidomide has been reported to be able of targeting the deletion of the long arm of chromosome 5 (del5q) clone. Its activity has been proven in MDS forms of low risk, with 5q deletion depending on transfusions. 6 The efficacy and toxicity of lenalidomide has been tested in patients with high-risk MDS or AML receiving lenalidomide 10 mg per day, 21 days a month, with 27% of global response. 7 The association of lenalidomide with hypomethylating agents has been tested in a phase I trial in patients with high-risk MDS and concluded that this association was well tolerated with encouraging clinical activity and acceptable toxicity. The go-forward dose was azacitidine 75 mg/m 2 on days 1 through 5 and lenalidomide 10 mg/m 2 on days 1 through 21. 8 We report here our experience of the combination of azacitidine and lenalidomide as first-line therapy for high-risk MDS and AML with complex karyotype, including abnormalities of the five chromosome. Eight consecutive patients were referred to our hematological department from August 2008 to March 2010, with a diagnosis of high-risk MDS or secondary AML. Characteristics of the patients at diagnosis are described in Table 1 . Median age was 66.5 years (range, 23-76). The median hemoglobin concentration at diagnosis was 9.1 g/dl (range, 1.7-11.2), median platelets level was 35 Â 10 9 /l (range, 6-107), and median WBC level was 2 Â 10 9 /l (range, 0.11-7.1). Median marrow blast percentage was 23% (range, 11-37%). Four patients had secondary therapy-related AML and four patients had type-2 refractory anemia with excess of blasts.
Treatment characteristics and evolution are shown in Table 2 . None of them was eligible for an ICT. All cases presented with a complex karyotype, including abnormalities on the chromosome 5. They received a combination of azacitidine and lenalidomide as first-line treatment. Median time from diagnosis to the beginning of treatment was 3.5 weeks (range, 2-8 weeks). Treatment schedule included azacitidine 75 mg/m 2 SC from day 1 to 5 in five patients, or to 7 in three patients, and oral lenalidomide 5 mg per day in one patient and 10 mg per day in seven patients for 15 or 21 days, every 28 days. They received a median of 4.5 cycles (range, 1-13 cycles).
All patients were hospitalized for the first cycle (median duration 25 days, range: 7-28) and then, when complications occurred. Main side effects were cytopenias: seven patients on the eight developed grade 4 thrombocytopenia. Five patients, four with baseline absolute neutrophil count more than 1000/ mm 3 developed grade 4 neutropenia. Severe infections occurred in neutropenic patients: six sepsis (four fevers of unknown origin, one facial cellulitis, one fungal infection and one cytomegalovirus reactivation), and two patients were transferred to intensive care unit because of septic shock. Other reported severe adverse effects were thrombosis (one case of transitory ischemic incident) and cardiac arrhythmia (one case). We noticed one case of grade 2 renal insufficiency, who required lenalidomide dose reduction to 5 mg per day. Five patients died: two with primary refractory disease at day 18 (sepsis) and day 100, and three with progressive disease after initial response.
Of the eight patients, six achieved a hematological response (three CR, three partial response), and two progressed under treatment ( Table 2 ). Among the six responding patients, initial responses occurred at a median of 10 weeks (range, 6-28 weeks) from the beginning of therapy. With a median follow-up of 60 weeks for the responding patients, (range, 0-72), four of the six responding patients relapsed at a median of 12 weeks (range, 8-36 weeks) from initial response. The other two patients (patients 1 and 2) are still alive in CR at 15 and 14 months after an allogeneic HSCT, respectively.
Patient 1 achieved cytologic, cytogenetic and molecular complete response after three cycles of azacitidine-lenalidomide; he was allografted with a matched-unrelated donor with a reduced intensity-conditioning regimen (fludarabine-IV busulfan-ATG) at time of best response. Seven months after transplantation, at the time of immunosuppression withdrawal, he developed an extensive form of chronic GVHD controlled by usual immunosuppressive therapy. At last follow-up, 15 months after transplantation, he is still in cytologic and molecular complete response of MDS, and of his primary disease (follicular lymphoma) that was detectable on the positron-emission tomography scan at the time of transplantation. Patient 2 achieved a cytologic response with persistence of partial cytogenetic abnormalities, after four cycles of azacitidine/ lenalidomide. He received an allogeneic matched-related HSCT after a reduced intensity conditioning (adapted-sequential conditioning 9 ). He did not develop GVHD and received three increasing doses of prophylactic donor lymphocyte injections (5 Â 10 6 to 5 Â 10 7 CD3 þ T cells/kg) starting by 5 months after HSCT, after complete withdrawal of immunosuppressive drugs. At latest follow-up, 14 months after HSCT, he is still alive in CR of the MDS and his primary disease (osteosarcoma diagnosed 9 years before HSCT), and without any clinical sign of GVHD.
Considering the whole population, with a median follow-up of 18 months, the median OS was 15 months (range, 1-18 months), and median progression-free survival was 9.5 months (range, 0-18 months).
Novel associations are clearly needed to improve the response rate and the OS of high-risk MDS and AML, with an acceptable toxicity profile. The justification for the strategy to combine two drugs, lenalidomide and azacitidine, rests in the theory that highrisk myeloid malignancies retained properties of the lower-risk MDS from which the disease likely evolved. 10 The mechanism of action of hypomethylating agents is not fully understood, but it is well documented that these drugs can induce gene hypomethylation in vivo.
2 Because of the possibility that these agents work via other mechanisms than induction of DNA hypomethylation, they have also been referred as DNA methyltransferase inhibitors or azanucleosides, based on the enzyme they inhibit or their structure, respectively.
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How lenalidomide induces response in myeloid malignancies remains unclear. Lenalidomide has a wide spectrum of potential mechanisms of action, including direct effects on the viability, growth, or survival of malignant cells, immunomodulation of T and NK cells, alteration of cytokine production, blockade of angiogenesis, and additional effects on the tumor microenvironment. 12 Thus, the use of two agents with complementary mechanisms of action may yield additive benefit.
In our study, among eight untreated patients with complex karyotype, two patients did not respond and died rapidly of their disease, four patients presented a transient response, but finally relapsed in the absence of intensification, and the two patients who were allografted after achieving a satisfactory response remained in remission at last follow-up over a year after transplantation. Side effects appeared acceptable and consisted mainly of hematologic toxicity that required to be closely monitored. These results should be compared with those of conventional chemotherapy where efficacy is poor, with often intolerable toxicity.
In conclusion, this association of lenalidomide and azacitidine may offer a possibility of remission with a tolerable toxicity. For patients considered for an allogeneic HSCT, the use in firstline therapy of these novel strategies rather than ICT is an interesting option, particularly in case of complex cytogenetics. These results are very promising, and developing innovating rational combinations seems to be a major step to improve the treatment of high-risk myeloid malignancies.
Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib 1 CCA in Ph-negative cells (CCA/PhÀ) are rarely found at CML diagnosis, but can be found in up to 8% of patients receiving imatinib or second generation tyrosine kinase inhibitors (TKIs). Some CCA/PhÀ, especially monosomy 7 or del(7q), predispose to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) development, whereas others (for example, trisomy 8) are usually transient. 2 There are reports of diploid acute leukemias (AML and ALL (acute lymphoid leukemia)) developing in CML patients receiving imatinib, without CCA/ PhÀ, but with antecedent myelodysplastic features. 3 Rare cases of AML developing in imatinib-treated CML patients with
